Friday, July 10, 2026

pharma · Acute myeloid leukemia · Juvenile idiopathic arthritis

Istituto Gentili Italia

Istituto Gentili S.r.l is a pharma organization headquartered in MILANO, IT. Primary therapeutic focus areas include Acute myeloid leukemia, Juvenile idiopathic arthritis, Malignant Pleural Mesothelioma, Osteogenesis Imp

Via San Giuseppe Cottolengo, 15, Milano, Lombardia 20143, IT HQ
1917 Founded
121 Employees
EMA registrant Type
Company details
Status
Public
HQ
Via San Giuseppe Cottolengo, 15, Milano, Lombardia 20143, IT
Founded
1917
Employees
121
Programs
50
Drugs
114
Patents
0
Clinical program

PLACEBO for amyotrophic lateral sclerosis

Phase 3 · small molecule · amyotrophic lateral sclerosis

PLACEBO for amyotrophic lateral sclerosis for amyotrophic lateral sclerosis is a Phase 3 program (small_molecule) at Istituto Gentili S.r.l. with 1 ClinicalTrials.gov record(s).

← All Istituto Gentili S.r.l. projects Phase 3 small molecule active

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Istituto Gentili S.r.l.
Phase
Phase 3
Modality
small_molecule
Indication
amyotrophic lateral sclerosis
Status
active
Trials
1

Clinical trials